Mifoglame (Sitagliptin)

Sitagliptin, the active ingredient in Mifoglame, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral administration. It works by enhancing the incretin system, thereby increasing insulin secretion and decreasing glucagon release, which helps lower blood glucose levels in adults diagnosed with type 2 diabetes mellitus.

GNH USA supplies Mifoglame as a licensed, Good Distribution Practice‑compliant pharmaceutical product, providing reliable international sourcing for hospitals, pharmacies and clinics that require quality‑assured antidiabetic medicines across global markets and consistent supply chains.

Mifoglame (sitagliptin) belongs to the DPP‑4 inhibitor class used to manage disorders of glucose metabolism.

- Type 2 diabetes mellitus: improves glycemic control when used with diet and exercise. - Combination therapy: added to metformin, sulfonylureas or insulin to achieve target HbA1c. - Monotherapy: can be prescribed as initial oral treatment for patients inadequately controlled on lifestyle alone.

Mifoglame is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Upper respiratory tract infection: symptoms of cold or flu. - Nasopharyngitis: sore throat and nasal congestion. - Diarrhea: loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia. - Hypersensitivity: skin eruptions or eosinophilia. - Hepatic injury: elevated liver enzymes. - Severe hypoglycemia: when combined with insulin or sulfonylureas.

Before initiating therapy, clinicians should consider several safety aspects.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: use with caution in patients with liver disease. - Hypoglycemia risk: monitor blood glucose when combined with insulin or sulfonylureas. - History of pancreatitis: avoid use in patients with prior pancreatic inflammation. - Pregnancy and lactation: prescribe only if potential benefit justifies potential risk. - Store at room temperature: keep in the original container, protect from moisture and light.

Sitagliptin may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Insulin: increased risk of hypoglycemia. - Sulfonylureas: additive hypoglycemic effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: possible alteration of glucose control. - Rifampin: may reduce sitagliptin exposure. - ACE inhibitors: monitor renal function and electrolytes. - Digoxin: observe for potential changes in serum concentration.